基因指导下的双联抗血小板治疗用于伴单个小皮质下梗死的轻型卒中或短暂性脑缺血发作
本研究为CHANCE-2试验的预设亚组分析,纳入2143例携带CYP2C19功能缺失等位基因的轻型卒中或TIA伴单个小皮质下梗死(SSSI)患者,比较替格瑞洛-阿司匹林与氯吡格雷-阿司匹林预防90天卒中复发的疗效与安全性。结果显示替格瑞洛-阿司匹林降低所有SSSI患者的卒中复发风险(HR 0.55,95%CI 0.38-0.78,p=0.001),在SSSI不伴责任颅内动脉狭窄(ICAS)患者中绝对风险降低更明显。
要点
- 替格瑞洛-阿司匹林较氯吡格雷-阿司匹林降低SSSI患者90天卒中复发风险(HR 0.55)。
- SSSI不伴ICAS者获益更显著(HR 0.45),SSSI伴ICAS者无显著差异(HR 1.20)。
- 重中度出血仅见于SSSI不伴ICAS患者(0.6% vs 0.6%)。
核心结论
- 在携带CYP2C19功能缺失等位基因的SSSI患者中,替格瑞洛-阿司匹林在降低90天卒中风险方面优于氯吡格雷-阿司匹林。
- 尽管不存在治疗与病因异质性的交互作用,但SSSI不伴ICAS患者的卒中绝对风险降低幅度大于SSSI伴ICAS患者。
研究设计与样本
- CHANCE-2试验的预设亚组分析,纳入发病24小时内随机分配的携带CYP2C19功能缺失等位基因的轻型卒中或TIA患者。
- 替格瑞洛-阿司匹林组:第1天替格瑞洛180 mg负荷剂量加安慰剂氯吡格雷,第2-90天替格瑞洛90 mg每日两次;氯吡格雷-阿司匹林组:第1天氯吡格雷300 mg负荷剂量加安慰剂替格瑞洛,第2-90天氯吡格雷75 mg每日一次;阿司匹林均在前21天使用。
- 纳入SSSI(弥散加权成像病灶直径≤20 mm)患者,并根据是否有责任颅内动脉狭窄(ICAS)分为SSSI+ICAS和SSSI-ICAS两型。
- 共纳入2143例符合条件患者,其中340例有责任ICAS,1803例无责任ICAS。
主要发现
- 替格瑞洛-阿司匹林较氯吡格雷-阿司匹林降低所有SSSI患者的卒中复发风险(HR 0.55;95%CI 0.38-0.78;p=0.001)。
- SSSI-ICAS患者中,替格瑞洛-阿司匹林组卒中复发35/901(3.9%),氯吡格雷-阿司匹林组72/902(8.0%)(HR 0.45;95%CI 0.29-0.68;p<0.001)。
- SSSI+ICAS患者中,替格瑞洛-阿司匹林组卒中复发14/176(8.0%),氯吡格雷-阿司匹林组13/164(7.9%)(HR 1.20;95%CI 0.45-3.23;p=0.71;交互作用p=0.08)。
- 重中度出血仅发生在SSSI-ICAS患者中(替格瑞洛-阿司匹林组5/901[0.6%] vs 氯吡格雷-阿司匹林组5/902[0.6%])。
关键数值与推荐
- 主要疗效结局为90天新发卒中。
- SSSI定义为弥散加权成像病灶直径≤20 mm。
- 证据等级:本研究提供II级证据,表明在成人急性轻型SSSI患者中,替格瑞洛联合阿司匹林较氯吡格雷联合阿司匹林降低卒中复发风险。
临床怎么用
- 对于携带CYP2C19功能缺失等位基因的急性轻型SSSI患者,作者结论认为替格瑞洛-阿司匹林在降低90天卒中风险方面优于氯吡格雷-阿司匹林。
- 亚组分析显示SSSI不伴ICAS患者绝对风险降低更明显,但原文未据此给出针对ICAS状态的推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Single small subcortical infarction (SSSI) is an important stroke subtype. The optimal antiplatelet medication for patients with ischemic stroke with an SSSI is still unclear. We aimed to test the efficacy and safety of ticagrelor-aspirin in preventing stroke recurrence among patients with SSSI in the Ticagrelor or Clopidogrel with Aspirin in High-Risk Patients with Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial. METHODS: In the CHANCE-2 trial, patients with a minor stroke or TIA who carried CYP2C19 loss-of-function (LOF) alleles were randomly assigned within 24 hours after symptom onset, to either ticagrelor-aspirin (placebo clopidogrel plus a 180 mg loading dose of ticagrelor on day 1, followed by 90 mg twice daily on days 2-90) or clopidogrel-aspirin (placebo ticagrelor plus a 300 mg loading dose of clopidogrel on day 1, followed by 75 mg daily on days 2-90). Aspirin was applied during the first 21 days. Patients who had an SSSI (diffusion-weighted imaging lesion diameter ≤20 mm) were included in this analysis and further categorized into 2 types according to whether they had the responsible intracranial artery stenosis (ICAS): SSSI + ICAS and SSSI - ICAS. The primary efficacy outcome was a new stroke at 90 days. RESULTS: Among 2,143 eligible patients, 340 had the responsible ICAS, and 1,803 did not. Ticagrelor-aspirin reduced stroke recurrence among all patients with SSSI (hazard ratio [HR]: 0.55; 95% CI 0.38-0.78; p = 0.001) compared with clopidogrel-aspirin. Stroke recurrence occurred in 35/901 (3.9%) patients with SSSI - ICAS on ticagrelor-aspirin and in 72/902 (8.0%) on clopidogrel-aspirin (hazard ratio [HR]: 0.45; 95% CI 0.29-0.68; p < 0.001). In patients with SSSI + ICAS, the corresponding event rates were 14/176 (8.0%) and 13/164 (7.9%), respectively (HR: 1.20; 95% CI 0.45-3.23; p = 0.71; p for interaction = 0.08). The risk of severe or moderate bleeding only occurred in patients with SSSI - ICAS (5/901 [0.6%] vs 5/902 [0.6%]). DISCUSSION: In this prespecified substudy, ticagrelor-aspirin was superior to clopidogrel-aspirin in reducing the risk of stroke at 90 days among patients with SSSI who carried CYP2C19 LOF allele(s). Although there was no treatment-by-heterogeneous etiology interaction, a greater absolute risk reduction of stroke was observed in patients with SSSI - ICAS than in those with SSSI + ICAS. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that ticagrelor and aspirin reduced the risk of stroke recurrence compared with clopidogrel with aspirin in adult patients with acute minor SSSI.
引用
- Liu H, Jing J, Wang A, et al. Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack With a Single Small Subcortical Infarction. Neurology. 2023. PMID: 36697242. doi:10.1212/WNL.0000000000206775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。